BioSpace News Archive

Merck, known as MSD outside the United States and Canada, announced that Rob Davis, chief executive officer and president, and Dr. Dean Li, president, Merck Research Laboratories, are scheduled to participate in a virtual fireside chat at the Morgan Stanley 19th Annual Conference on Sept. 13, 2021, at 11:00 a.m. EDT.

Eagle Pharmaceuticals, Inc. will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows:.

Merck, known as MSD outside the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration in China in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or gastroesophageal junction.

Orchard Therapeutics, a global gene therapy leader, announced that the Compensation Committee of Orchard’s Board of Directors approved the grant of non-statutory stock options to four new employees to purchase an aggregate of 278,500 ordinary shares under Orchard’s 2020 Inducement Equity Plan.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that EyePoint Pharmaceuticals’ senior management team will present at the following four upcoming conferences.

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, reported that Maxine Gowen, Ph.D., has been appointed chairwoman of the board of directors for the company, effective August 31.